Figure 3.

Kinetics of CD14⁺ cells and neutrophils with or without bound platelets and their PD-L1 expression in NSCLC patients based on anti-PD-(L)1 response. (A,B) CD14⁺ cells and (C,D) neutrophils with bound platelets and their evolution throughout 22–24 weeks of treatment in PD (n = 55), SD (n = 24), and R patients (n = 34). White dots represent patients with complete response and green dots patients with partial response. Kinetics of PD-L1⁺ (E) CD14⁺ cells and (F) neutrophils without bound platelets during 24 weeks of anti-PD-(L)1 therapy. p-values from one-way ANOVAs for each of the three groups are displayed on the right side of each graph, and significant differences between successive time intervals are analyzed by the Tukey post hoc comparisons and marked with a line. (G) Comparison of pretreatment baseline percentages of PD-L1⁺ CD14⁺ cells and PD-L1⁺ neutrophils with or without bound platelets among NSCLC classified according to their response to anti-PD-(L)1 therapy. Statistical analyses between three groups of patients were performed using Kruskal–Wallis test with Dunn’s correction (showed in the table). (*) p < 0.05; n.s. is not significant.